PL385388A1 - Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, cząsteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub białka - Google Patents

Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, cząsteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub białka

Info

Publication number
PL385388A1
PL385388A1 PL385388A PL38538808A PL385388A1 PL 385388 A1 PL385388 A1 PL 385388A1 PL 385388 A PL385388 A PL 385388A PL 38538808 A PL38538808 A PL 38538808A PL 385388 A1 PL385388 A1 PL 385388A1
Authority
PL
Poland
Prior art keywords
rna
obtaining
dinucleotides
protein
application
Prior art date
Application number
PL385388A
Other languages
English (en)
Other versions
PL215513B1 (pl
Inventor
Joanna Kowalska
Jacek Jemielity
Edward Darżynkiewicz
Maciej Roman Łukaszewicz
Joanna Żuberek
Original Assignee
Uniwersytet Warszawski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Warszawski filed Critical Uniwersytet Warszawski
Priority to PL385388A priority Critical patent/PL215513B1/pl
Priority to US12/996,243 priority patent/US8519110B2/en
Priority to ES09759412T priority patent/ES2425781T3/es
Priority to AU2009256131A priority patent/AU2009256131B2/en
Priority to EP09759412.1A priority patent/EP2297175B1/en
Priority to JP2011512643A priority patent/JP5715560B2/ja
Priority to PL09759412T priority patent/PL2297175T3/pl
Priority to CA2727091A priority patent/CA2727091C/en
Priority to PCT/US2009/046249 priority patent/WO2009149253A2/en
Publication of PL385388A1 publication Critical patent/PL385388A1/pl
Publication of PL215513B1 publication Critical patent/PL215513B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL385388A 2008-06-06 2008-06-06 Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka PL215513B1 (pl)

Priority Applications (9)

Application Number Priority Date Filing Date Title
PL385388A PL215513B1 (pl) 2008-06-06 2008-06-06 Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
US12/996,243 US8519110B2 (en) 2008-06-06 2009-06-04 mRNA cap analogs
ES09759412T ES2425781T3 (es) 2008-06-06 2009-06-04 Análogos de CAP de ARNm
AU2009256131A AU2009256131B2 (en) 2008-06-06 2009-06-04 mRNA cap analogs
EP09759412.1A EP2297175B1 (en) 2008-06-06 2009-06-04 Mrna cap analogs
JP2011512643A JP5715560B2 (ja) 2008-06-06 2009-06-04 ｍＲＮＡ ＣＡＰ類似体
PL09759412T PL2297175T3 (pl) 2008-06-06 2009-06-04 Analogi czapeczki mRNA
CA2727091A CA2727091C (en) 2008-06-06 2009-06-04 Mrna cap analogs
PCT/US2009/046249 WO2009149253A2 (en) 2008-06-06 2009-06-04 Mrna cap analogs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL385388A PL215513B1 (pl) 2008-06-06 2008-06-06 Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka

Publications (2)

Publication Number Publication Date
PL385388A1 true PL385388A1 (pl) 2009-12-07
PL215513B1 PL215513B1 (pl) 2013-12-31

Family

ID=41398862

Family Applications (2)

Application Number Title Priority Date Filing Date
PL385388A PL215513B1 (pl) 2008-06-06 2008-06-06 Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
PL09759412T PL2297175T3 (pl) 2008-06-06 2009-06-04 Analogi czapeczki mRNA

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL09759412T PL2297175T3 (pl) 2008-06-06 2009-06-04 Analogi czapeczki mRNA

Country Status (8)

Country Link
US (1) US8519110B2 (pl)
EP (1) EP2297175B1 (pl)
JP (1) JP5715560B2 (pl)
AU (1) AU2009256131B2 (pl)
CA (1) CA2727091C (pl)
ES (1) ES2425781T3 (pl)
PL (2) PL215513B1 (pl)
WO (1) WO2009149253A2 (pl)

Families Citing this family (289)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
WO2013143555A1 (en) * 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
CN103254260B (zh) * 2013-02-07 2015-11-11 江西科技师范大学 由核苷氢亚磷酸单酯合成对称双核苷二磷酸二钠盐的方法
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
EP2971033B8 (en) * 2013-03-15 2019-07-10 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
EP4279610A3 (en) 2013-03-15 2024-01-03 ModernaTX, Inc. Ribonucleic acid purification
PL3019619T3 (pl) 2013-07-11 2022-01-10 Modernatx, Inc. Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
SG11201604198YA (en) 2013-12-30 2016-07-28 Curevac Ag Methods for rna analysis
EP3090060B2 (en) 2013-12-30 2025-05-21 CureVac Manufacturing GmbH Methods for rna analysis
SG11201608605QA (en) 2014-06-10 2016-12-29 Curevac Ag Methods and means for enhancing rna production
US10286086B2 (en) 2014-06-19 2019-05-14 Modernatx, Inc. Alternative nucleic acid molecules and uses thereof
AU2015289656A1 (en) 2014-07-16 2017-02-16 Modernatx, Inc. Circular polynucleotides
WO2016011226A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3171895A1 (en) 2014-07-23 2017-05-31 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
EP3461904A1 (en) 2014-11-10 2019-04-03 ModernaTX, Inc. Alternative nucleic acid molecules containing reduced uracil content and uses thereof
US10676499B2 (en) 2014-12-16 2020-06-09 Novartis Ag 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA
EP4019635A1 (en) 2015-03-25 2022-06-29 Editas Medicine, Inc. Crispr/cas-related methods, compositions and components
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
CA2985615A1 (en) 2015-05-11 2016-11-17 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating hiv infection and aids
CA2986310A1 (en) 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
DK3303583T3 (da) 2015-05-29 2020-07-13 Curevac Real Estate Gmbh Fremgangsmåde til fremstilling og oprensning af rna, omfattende mindst et trin til tangential-flow-filtrering
US11911415B2 (en) 2015-06-09 2024-02-27 Editas Medicine, Inc. CRISPR/Cas-related methods and compositions for improving transplantation
EP4239080A3 (en) 2015-07-01 2023-11-01 CureVac Manufacturing GmbH Method for analysis of an rna molecule
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
HRP20220156T1 (hr) 2015-09-17 2022-04-15 Modernatx, Inc. Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
EP4101930A1 (en) 2015-09-17 2022-12-14 ModernaTX, Inc. Polynucleotides containing a stabilizing tail region
EP3359670B2 (en) 2015-10-05 2024-02-14 ModernaTX, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
WO2017066789A1 (en) * 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
US11866754B2 (en) 2015-10-16 2024-01-09 Modernatx, Inc. Trinucleotide mRNA cap analogs
DK3362461T3 (da) 2015-10-16 2022-05-09 Modernatx Inc Mrna-cap-analoger med modificeret phosphatbinding
CA3001351A1 (en) 2015-10-21 2017-04-27 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating hepatitis b virus
CN109312338B (zh) 2015-10-30 2022-09-27 爱迪塔斯医药公司 治疗单纯疱疹病毒的crispr/cas相关方法及组合物
RS63051B1 (sr) 2015-12-22 2022-04-29 Modernatx Inc Jedinjenja i kompozicije za intracelularnu isporuku agenasa
EP3394280A1 (en) 2015-12-23 2018-10-31 CureVac AG Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
SMT202200310T1 (it) 2015-12-23 2022-09-14 Modernatx Inc Metodi di utilizzo dei polinucleotidi codificanti il ligando di ox40
US20190241658A1 (en) 2016-01-10 2019-08-08 Modernatx, Inc. Therapeutic mRNAs encoding anti CTLA-4 antibodies
PL415967A1 (pl) * 2016-01-29 2017-07-31 Univ Warszawski 5'-tiofosforanowe analogi końca 5' mRNA (kapu), sposób ich otrzymywania i zastosowanie
US12612654B2 (en) 2016-02-12 2026-04-28 CureVac SE Method for analyzing RNA
US20190049414A1 (en) 2016-02-15 2019-02-14 Curevac Ag Method for analyzing by-products of rna in vitro transcription
EP3423595A1 (en) 2016-03-03 2019-01-09 CureVac AG Rna analysis by total hydrolysis
WO2017162265A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
WO2017162266A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Rna replicon for versatile and efficient gene expression
EP3442590A2 (en) 2016-04-13 2019-02-20 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
EP4631970A3 (en) 2016-05-04 2026-01-07 CureVac SE Nucleic acid molecules and uses thereof
EP4233898A3 (en) 2016-05-04 2023-11-01 CureVac SE Influenza mrna vaccines
EP3452499A2 (en) 2016-05-06 2019-03-13 Juno Therapeutics, Inc. Genetically engineered cells and methods of making the same
US11001861B2 (en) 2016-05-18 2021-05-11 Modernatx, Inc. Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
AU2017268396B2 (en) 2016-05-18 2023-05-18 Modernatx, Inc. Polynucleotides encoding citrin for the treatment of citrullinemia type 2
JP7114485B2 (ja) 2016-05-18 2022-08-08 モデルナティエックス インコーポレイテッド ファブリー病の治療のためのα－ガラクトシダーゼＡをコードするポリヌクレオチド
PL3458083T3 (pl) 2016-05-18 2023-03-13 Modernatx, Inc. Polinukleotydy kodujące interleukinę-12 (il12) i ich zastosowania
CA3024624A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
US12128113B2 (en) 2016-05-18 2024-10-29 Modernatx, Inc. Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
WO2017201332A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding acyl-coa dehydrogenase, very long-chain for the treatment of very long-chain acyl-coa dehydrogenase deficiency
RS63625B1 (sr) 2016-05-18 2022-10-31 Modernatx Inc Kombinacije irnk koje kodiraju imunomodulirajuće polipeptide i njihova upotreba
EP3468537A1 (en) 2016-06-14 2019-04-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US12385034B2 (en) 2016-06-24 2025-08-12 Modernatx, Inc. Methods and apparatus for filtration
CN109715205A (zh) 2016-08-19 2019-05-03 库瑞瓦格股份公司 用于癌症治疗的rna
KR20190093816A (ko) 2016-10-26 2019-08-26 큐어백 아게 지질 나노입자 mRNA 백신
EP3538067A1 (en) 2016-11-08 2019-09-18 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
WO2018115527A2 (en) 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
WO2018115507A2 (en) 2016-12-23 2018-06-28 Curevac Ag Henipavirus vaccine
AU2018224387B2 (en) 2017-02-22 2024-08-08 Crispr Therapeutics Ag Compositions and methods for gene editing
JP7332478B2 (ja) 2017-03-15 2023-08-23 モデルナティエックス インコーポレイテッド 脂質ナノ粒子製剤
RS63953B1 (sr) 2017-03-15 2023-02-28 Modernatx Inc Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
WO2018208998A1 (en) 2017-05-10 2018-11-15 The Regents Of The University Of California Directed editing of cellular rna via nuclear delivery of crispr/cas9
EP4253544A3 (en) 2017-05-18 2023-12-20 ModernaTX, Inc. Modified messenger rna comprising functional rna elements
AU2018270111B2 (en) 2017-05-18 2022-07-14 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
US20200131498A1 (en) 2017-06-14 2020-04-30 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
EP3638678B1 (en) 2017-06-14 2025-12-03 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
EP3638292A1 (en) 2017-06-14 2020-04-22 ModernaTX, Inc. Polynucleotides encoding coagulation factor viii
US10034951B1 (en) 2017-06-21 2018-07-31 New England Biolabs, Inc. Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity
JP7722629B2 (ja) 2017-07-04 2025-08-13 キュアバック エスイー 新規核酸分子
US20200362382A1 (en) 2017-08-18 2020-11-19 Modernatx, Inc. Methods of preparing modified rna
US11602557B2 (en) 2017-08-22 2023-03-14 Cure Vac SE Bunyavirales vaccine
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
US12291717B2 (en) 2017-09-13 2025-05-06 Biontech Rna Pharmaceuticals Gmbh RNA replicon for reprogramming somatic cells
AU2018333530B2 (en) 2017-09-13 2024-05-30 Biontech Cell & Gene Therapies Gmbh RNA replicon for expressing a T cell receptor or an artificial T cell receptor
EP3681901B1 (en) 2017-09-13 2024-03-27 BioNTech SE Method of enhancing rna expression in a cell
SG11202003247RA (en) 2017-11-08 2020-05-28 Curevac Ag Rna sequence adaptation
US11939601B2 (en) 2017-11-22 2024-03-26 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
JP7424976B2 (ja) 2017-11-22 2024-01-30 モダーナティエックス・インコーポレイテッド プロピオン酸血症の治療用のプロピオニルＣｏＡカルボキシラーゼアルファ及びベータサブユニットをコードするポリヌクレオチド
EP3714048B1 (en) 2017-11-22 2025-04-09 ModernaTX, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
US11931406B2 (en) 2017-12-13 2024-03-19 CureVac SE Flavivirus vaccine
CN111511928A (zh) 2017-12-21 2020-08-07 库瑞瓦格股份公司 偶联到单一支持物或标签的线性双链dna和用于制备所述线性双链dna的方法
US11802146B2 (en) 2018-01-05 2023-10-31 Modernatx, Inc. Polynucleotides encoding anti-chikungunya virus antibodies
EP3773702A2 (en) 2018-04-05 2021-02-17 CureVac AG Novel yellow fever nucleic acid molecules for vaccination
US20210163928A1 (en) 2018-04-11 2021-06-03 Modernatx, Inc. Messenger rna comprising functional rna elements
CA3091558A1 (en) 2018-04-17 2019-10-24 Curevac Ag Novel rsv rna molecules and compositions for vaccination
FR3081169B1 (fr) * 2018-05-15 2020-06-19 Messenger Biopharma Substitution de la coiffe des arn messagers par deux sequences d'arn introduites a leur extremite 5'
US20210260178A1 (en) 2018-06-27 2021-08-26 Curevac Ag Novel lassa virus rna molecules and compositions for vaccination
WO2020023390A1 (en) 2018-07-25 2020-01-30 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
MA53545A (fr) 2018-09-02 2021-07-14 Modernatx Inc Polynucléotides codant pour l'acyl-coa déshydrogénase à très longue chaîne pour le traitement de l'insuffisance en acyl-coa déshydrogénase à très longue chaîne
JP2022500436A (ja) 2018-09-13 2022-01-04 モダーナティエックス・インコーポレイテッドModernaTX, Inc. 糖原病を処置するためのグルコース−６−ホスファターゼをコードするポリヌクレオチド
US12644102B2 (en) 2018-09-13 2026-06-02 Modernatx, Inc. Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex E1-α, E1-β, and E2 subunits for the treatment of maple syrup urine disease
MA53615A (fr) 2018-09-14 2021-07-21 Modernatx Inc Polynucléotides codant pour le polypeptide a1, de la famille de l'uridine diphosphate glycosyltransférase 1, pour le traitement du syndrome de crigler-najjar
EP3853202A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
WO2020069169A1 (en) 2018-09-27 2020-04-02 Modernatx, Inc. Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
CA3114892A1 (en) 2018-10-04 2020-04-09 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed rna
US11072808B2 (en) * 2018-10-04 2021-07-27 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed RNA
AU2019410737A1 (en) 2018-12-21 2021-06-10 CureVac SE RNA for malaria vaccines
CA3122645A1 (en) 2018-12-21 2020-06-25 Curevac Ag Methods for rna analysis
CN113939282A (zh) 2019-01-31 2022-01-14 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
KR20210133218A (ko) 2019-01-31 2021-11-05 모더나티엑스, 인크. 볼텍스 믹서 및 연계된 방법, 시스템 및 이의 장치
EP3920950A1 (en) 2019-02-08 2021-12-15 CureVac AG Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
US12637682B2 (en) 2019-04-16 2026-05-26 The Regents Of The University Of California Protein translational control
WO2020227642A1 (en) 2019-05-08 2020-11-12 Modernatx, Inc. Compositions for skin and wounds and methods of use thereof
WO2020227615A1 (en) 2019-05-08 2020-11-12 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
EP3986452A1 (en) 2019-06-18 2022-04-27 CureVac AG Rotavirus mrna vaccine
EP3987027A1 (en) 2019-06-24 2022-04-27 ModernaTX, Inc. Endonuclease-resistant messenger rna and uses thereof
MA56517A (fr) 2019-06-24 2022-04-27 Modernatx Inc Arn messager comprenant des éléments d'arn fonctionnels et leurs utilisations
WO2021026358A1 (en) 2019-08-07 2021-02-11 Moderna TX, Inc. Compositions and methods for enhanced delivery of agents
WO2021028439A1 (en) 2019-08-14 2021-02-18 Curevac Ag Rna combinations and compositions with decreased immunostimulatory properties
CA3158013A1 (en) 2019-10-15 2021-04-22 Modernatx, Inc. Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease
CA3162019A1 (en) 2019-12-20 2021-06-24 Gemma NAVARRO Lipid nanoparticles for delivery of nucleic acids
DE202021004130U1 (de) 2020-02-04 2022-10-26 Curevac Ag Coronavirus-Vakzine
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
PL432884A1 (pl) * 2020-02-12 2021-08-16 Uniwersytet Warszawski Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
WO2021204179A1 (en) 2020-04-09 2021-10-14 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for coronavirus
TWI899203B (zh) 2020-04-09 2025-10-01 大陸商蘇州艾博生物科技有限公司 脂質奈米粒子組成物
CN118490818A (zh) 2020-04-22 2024-08-16 生物技术欧洲股份公司 冠状病毒疫苗
AU2021270587A1 (en) 2020-05-14 2022-12-08 Modernatx, Inc. LNP compositions comprising an mRNA therapeutic and an effector molecule
WO2021239880A1 (en) 2020-05-29 2021-12-02 Curevac Ag Nucleic acid based combination vaccines
AU2021285812A1 (en) 2020-06-01 2023-01-05 Modernatx, Inc. Phenylalanine hydroxylase variants and uses thereof
WO2021247535A1 (en) 2020-06-01 2021-12-09 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
JP7769644B2 (ja) 2020-06-04 2025-11-13 バイオエヌテック エスエー 多用途かつ効率的な遺伝子発現のためのｒｎａレプリコン
IL299196A (en) 2020-06-23 2023-02-01 Modernatx Inc LNP preparations that include mRNA treatments with extended lifespan
AU2021301922A1 (en) 2020-06-30 2023-02-02 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
JP2023535225A (ja) 2020-07-24 2023-08-16 ストランド セラピューティクス インコーポレイテッド 改変ヌクレオチドを含む脂質ナノ粒子
EP4172194A1 (en) 2020-07-31 2023-05-03 CureVac SE Nucleic acid encoded antibody mixtures
TW202214566A (zh) 2020-08-20 2022-04-16 大陸商蘇州艾博生物科技有限公司 脂質化合物及脂質奈米粒子組合物
WO2022043551A2 (en) 2020-08-31 2022-03-03 Curevac Ag Multivalent nucleic acid based coronavirus vaccines
CN116368226A (zh) 2020-09-04 2023-06-30 维乎医疗有限公司 用于加帽rna的组合物和方法
MX2023004371A (es) 2020-10-14 2023-07-26 George Mason Res Foundation Inc Lípidos ionizables, y métodos de fabricación y uso de los mismos.
CA3199784A1 (en) 2020-11-13 2022-05-19 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
US20230414516A1 (en) 2020-11-16 2023-12-28 BioNTech SE Enhanced formulation stabilization and improved lyophilization processes
KR20230129432A (ko) 2020-12-09 2023-09-08 비온테크 에스이 Rna 제조
MX2023007574A (es) 2020-12-22 2023-09-29 CureVac SE "vacuna de arn contra variantes de sars-cov-2.
US20240299309A1 (en) 2020-12-22 2024-09-12 CureVac SE Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
KR20230129479A (ko) 2021-01-08 2023-09-08 스트랜드 세러퓨틱스 인코포레이티드 발현 구성체 및 이의 용도
CN116615472A (zh) 2021-01-14 2023-08-18 苏州艾博生物科技有限公司 聚合物缀合的脂质化合物和脂质纳米颗粒组合物
WO2022152109A2 (en) 2021-01-14 2022-07-21 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
CA3170747A1 (en) 2021-01-27 2022-08-04 Moritz THRAN Method of reducing the immunostimulatory properties of in vitro transcribed rna
WO2022174079A1 (en) 2021-02-12 2022-08-18 Modernatx, Inc. Lnp compositions comprising payloads for in vivo therapy
WO2022204369A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
US20240207374A1 (en) 2021-03-24 2024-06-27 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
US20240189449A1 (en) 2021-03-24 2024-06-13 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
WO2022204390A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
WO2022204380A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
EP4313152A1 (en) 2021-03-26 2024-02-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
EP4312988A2 (en) 2021-03-31 2024-02-07 CureVac SE Syringes containing pharmaceutical compositions comprising rna
US20240175005A1 (en) 2021-03-31 2024-05-30 Modernatx, Inc. PURIFICATION AND RECYCLING OF mRNA NUCLEOTIDE CAPS
JP2024512780A (ja) 2021-04-01 2024-03-19 モデルナティエックス インコーポレイテッド 多価ｒｎａ組成物中のｒｎａ種の識別及び比率決定のための方法
WO2022234417A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Immunogenic composition against influenza
CA3171589A1 (en) 2021-05-03 2022-11-03 Moritz THRAN Improved nucleic acid sequence for cell type specific expression
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
CA3218544A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2022246020A1 (en) 2021-05-19 2022-11-24 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
AU2022281746B2 (en) 2021-05-24 2025-01-16 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
US20240384277A1 (en) 2021-06-15 2024-11-21 Modernatx, Inc. Engineered polynucleotides for cell-type or microenvironment-specific expression
US20240376445A1 (en) 2021-06-22 2024-11-14 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
US20240316165A1 (en) 2021-07-12 2024-09-26 Modernatx, Inc. Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
WO2023009499A1 (en) 2021-07-27 2023-02-02 Modernatx, Inc. Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease type 1a (gsd1a)
WO2023007019A1 (en) 2021-07-30 2023-02-02 CureVac SE Cap analogs having an acyclic linker to the guanine derivative nucleobase
EP4377331A2 (en) 2021-07-30 2024-06-05 CureVac SE Mrnas for treatment or prophylaxis of liver diseases
AU2021461416A1 (en) 2021-08-24 2024-02-22 BioNTech SE In vitro transcription technologies
IL309502A (en) 2021-09-03 2024-02-01 CureVac SE Lipid nanoparticles for nucleic acid delivery involving phosphatidylserine
EP4763287A2 (en) 2021-09-03 2026-06-24 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
US20250017867A1 (en) 2021-10-01 2025-01-16 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
JP7883580B2 (ja) 2021-10-08 2026-07-01 スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド 脂質化合物及び脂質ナノ粒子組成物
CN116064598B (zh) 2021-10-08 2024-03-12 苏州艾博生物科技有限公司 冠状病毒的核酸疫苗
AR127312A1 (es) 2021-10-08 2024-01-10 Suzhou Abogen Biosciences Co Ltd Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
KR20240099256A (ko) 2021-10-08 2024-06-28 화이자 인코포레이티드 면역원성 lnp 조성물 및 이의 방법
US20250236883A1 (en) 2021-10-18 2025-07-24 BioNTech SE Modified replicable rna and related compositions and their use
EP4419708A1 (en) 2021-10-18 2024-08-28 BioNTech SE Methods for determining mutations for increasing modified replicable rna function and related compositions and their use
EP4426340A1 (en) 2021-11-01 2024-09-11 ModernaTX, Inc. Polynucleotides encoding integrin beta-6 and methods of use thereof
AU2022391744A1 (en) 2021-11-18 2024-06-27 Cornell University Microrna-dependent mrna switches for tissue-specific mrna-based therapies
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
EP4448002A1 (en) 2021-12-17 2024-10-23 Pfizer Inc. Polynucleotide compositions and uses thereof
JP2025502599A (ja) 2021-12-23 2025-01-28 スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド 脂質化合物及び脂質ナノ粒子組成物
WO2023138786A1 (en) 2022-01-21 2023-07-27 BioNTech SE Analysis of rna molecules using catalytic nucleic acids
EP4469091A1 (en) 2022-01-28 2024-12-04 CureVac SE Nucleic acid encoded transcription factor inhibitors
EP4479085A1 (en) 2022-02-18 2024-12-25 ModernaTX, Inc. Mrnas encoding checkpoint cancer vaccines and uses thereof
WO2023166425A1 (en) 2022-03-01 2023-09-07 Crispr Therapeutics Ag Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
US20230293646A1 (en) 2022-03-21 2023-09-21 Crispr Therapeutics Ag Methods and compositions for treating lipoprotein-related diseases
WO2023183909A2 (en) 2022-03-25 2023-09-28 Modernatx, Inc. Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
WO2023196399A1 (en) 2022-04-06 2023-10-12 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria
EP4508201A1 (en) 2022-04-14 2025-02-19 ModernaTX, Inc. Rna polymerase variants
AU2023262576A1 (en) 2022-04-26 2024-10-10 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
WO2023213378A1 (en) 2022-05-02 2023-11-09 BioNTech SE Replicon compositions and methods of using same for the treatment of diseases
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
CA3248209A1 (en) 2022-05-25 2023-11-30 CureVac SE Escherichia coli Antigenic Polypeptide-Based Nucleic Acid Vaccine (FIMH)
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024017479A1 (en) 2022-07-21 2024-01-25 BioNTech SE Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production
EP4562163A1 (en) 2022-07-26 2025-06-04 ModernaTX, Inc. Engineered polynucleotides for temporal control of expression
CA3262766A1 (en) 2022-07-28 2024-02-01 Stemcell Technologies Canada Inc. Polynucleotides encoding bound antigens and their uses
JP2025527583A (ja) 2022-08-18 2025-08-22 スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド 脂質ナノ粒子の組成物
WO2024056856A1 (en) 2022-09-15 2024-03-21 BioNTech SE Systems and compositions comprising trans-amplifying rna vectors with mirna
US20250387764A1 (en) 2022-09-15 2025-12-25 Pfizer Inc. Coaxial flow device for nanoparticle preparation and manufacturing equipment including such device
CA3267272A1 (en) 2022-09-26 2024-04-04 Glaxosmithkline Biologicals Sa FLU VIRUS VACCINES
US20260130987A1 (en) 2022-10-19 2026-05-14 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
US20260191905A1 (en) 2022-12-01 2026-07-09 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
WO2024119117A1 (en) * 2022-12-02 2024-06-06 Prime Medicine, Inc. Modified 5' cap for mrna and methods of use thereof
WO2024130158A1 (en) 2022-12-16 2024-06-20 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
US20260216313A1 (en) 2022-12-23 2026-07-30 Pfizer Inc. Lipid particle compositions and methods of use thereof
EP4648793A1 (en) 2023-01-11 2025-11-19 ModernaTX, Inc. Personalized cancer vaccines
WO2024154061A1 (en) 2023-01-18 2024-07-25 Pfizer Inc. Compositions and methods for stabilizing rna
US20260226091A1 (en) 2023-01-31 2026-08-06 CureVac SE Cap analogs with 5'-terminal acyclic guanosine derivative
WO2024160936A1 (en) 2023-02-03 2024-08-08 Glaxosmithkline Biologicals Sa Rna formulation
WO2024165146A1 (en) 2023-02-07 2024-08-15 Biontech Cell & Gene Therapies Gmbh Immune effector cells stably and transiently expressing nucleic acids
EP4665390A1 (en) 2023-02-13 2025-12-24 Pfizer Inc. Immunogenic composition against influenza
GB202302092D0 (en) 2023-02-14 2023-03-29 Glaxosmithkline Biologicals Sa Analytical method
WO2024178305A1 (en) 2023-02-24 2024-08-29 Modernatx, Inc. Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer
WO2024182301A2 (en) 2023-02-27 2024-09-06 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding galactose-1-phosphate uridylyltransferase (galt) for the treatment of galactosemia
KR20250153298A (ko) 2023-03-08 2025-10-24 큐어백 에스이 핵산 전달을 위한 신규의 지질 나노입자 제형
WO2024197033A1 (en) 2023-03-21 2024-09-26 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of heart failure
WO2024206126A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Cd16-binding antibodies and uses thereof
WO2024206329A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Nucleic acid molecules encoding bi-specific secreted engagers and uses thereof
WO2024200820A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
JP2026512425A (ja) 2023-03-30 2026-04-16 オーエスイー・イミュノセラピューティクス 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用
KR20260003656A (ko) 2023-04-12 2026-01-07 스트랜드 세러퓨틱스 인코포레이티드 합성 회로 및 이의 용도
EP4694922A1 (en) 2023-04-14 2026-02-18 BioNTech SE Hiv vaccine
JP2026518411A (ja) 2023-04-27 2026-06-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザウイルスワクチン
EP4701657A1 (en) 2023-04-27 2026-03-04 GlaxoSmithKline Biologicals S.A. Influenza virus vaccines
EP4704816A1 (en) 2023-05-03 2026-03-11 ModernaTX, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
EP4464713A1 (en) 2023-05-18 2024-11-20 Siec Badawcza Lukasiewicz - PORT Polski Osrodek Rozwoju Technologii Circular rna analogs, preparation and application thereof
JP2026521505A (ja) 2023-06-14 2026-06-30 ファイザー・インク Ｒｎａを安定化するための方法
WO2025022290A1 (en) 2023-07-21 2025-01-30 Crispr Therapeutics Ag Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene
KR20260042228A (ko) 2023-07-24 2026-03-30 스트랜드 세러퓨틱스 인코포레이티드 체외 세포 요법을 위한 조작된 면역 세포를 생산하기 위한 rna 기반 합성 회로
KR20260046366A (ko) 2023-07-25 2026-04-07 스트랜드 세러퓨틱스 인코포레이티드 마이크로 rna 비표적화 센서를 포함하는 폴리뉴클레오타이드 및 이의 용도
EP4754109A2 (en) 2023-08-03 2026-06-10 TriLink BioTechnologies, LLC Cap analogs and methods of use thereof
WO2025042806A2 (en) 2023-08-21 2025-02-27 Modernatx, Inc. C-met binding antibodies, nucleic acids encoding same, and methods of use
WO2025051381A1 (en) 2023-09-08 2025-03-13 BioNTech SE Methods and compositions for localized expression of administered rna
AU2024342024A1 (en) 2023-09-13 2026-03-26 Pfizer Inc. Immunogenic compositions against influenza
WO2025059290A1 (en) 2023-09-14 2025-03-20 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
WO2025072482A1 (en) 2023-09-27 2025-04-03 Modernatx, Inc. Immunoglobulin a protease polypeptides, polynucleotides, and uses thereof
EP4788369A2 (en) 2023-10-06 2026-08-12 Pfizer Inc. Immunogenic compositions
US20250332245A1 (en) 2023-11-15 2025-10-30 Pfizer Inc. Immunogenic compositions against influenza
AU2024384477A1 (en) 2023-11-21 2026-05-21 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
WO2025132839A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Biologicals Sa Influenza virus vaccines
KR20250106372A (ko) 2024-01-02 2025-07-10 한국과학기술원 선천면역을 조절할 수 있는 헤어핀 구조의 핵산분자 및 이의 용도
WO2025171182A1 (en) 2024-02-08 2025-08-14 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
WO2025181704A2 (en) 2024-02-27 2025-09-04 Crispr Therapeutics Ag Rt editing compositions and methods
WO2025184429A1 (en) 2024-02-28 2025-09-04 Modernatx, Inc. Bromodomain and extra-terminal domain (bet) epigenetic reader decoy
WO2025186726A1 (en) 2024-03-05 2025-09-12 Crispr Therapeutics Ag Modulating expression of agt (angiotensinogen) gene
WO2025186725A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Improved lnp formulations and uses thereof
TW202602467A (zh) 2024-03-11 2026-01-16 美商輝瑞股份有限公司 包含經共軛之大腸桿菌糖的免疫原性組成物及其用途
US20260061042A1 (en) 2024-03-26 2026-03-05 Pfizer Inc. Polynucleotide compositions and uses thereof
GB202404607D0 (en) 2024-03-29 2024-05-15 Glaxosmithkline Biologicals Sa RNA formulation
WO2025212851A2 (en) 2024-04-03 2025-10-09 Orbital Therapeutics, Inc. mRNA COMPOSITIONS AND USES THEREOF IN VARICELLA ZOSTER VIRUS VACCINES
WO2025217591A1 (en) 2024-04-12 2025-10-16 Strand Therapeutics Inc. Human-derived synthetic regulators and uses thereof
WO2025238563A1 (en) 2024-05-17 2025-11-20 Pfizer Inc. Coaxial mixing device for nanoparticle preparation and manufacturing equipment including such mixing device
WO2025255199A1 (en) 2024-06-05 2025-12-11 Modernatx, Inc. Argininosuccinate synthase 1 and argininosuccinate lyase polypeptides and polynucleotides and uses thereof
WO2026025031A1 (en) 2024-07-26 2026-01-29 Modernatx, Inc. Mrna encoding mageb2 tcer molecule
WO2026044055A1 (en) 2024-08-23 2026-02-26 Modernatx, Inc. Muc16 binding molecules, nucleic acids encoding same, and methods of use
WO2026075820A1 (en) 2024-10-03 2026-04-09 Modernatx, Inc. 4-1bb binding molecules, nucleic acids encoding same, and methods of use
WO2026085234A1 (en) 2024-10-18 2026-04-23 Modernatx, Inc. 3' untranslated region sequences for extending messenger ribonucleic acids half-life
WO2026088119A1 (en) 2024-10-24 2026-04-30 Pfizer Inc. Lipidated tlr7/8 modulators as adjuvants and uses thereof
WO2026096575A1 (en) 2024-10-29 2026-05-07 Modernatx, Inc. Mrna encoding concatemeric prame epitope polypeptide
WO2026106497A2 (en) 2024-11-18 2026-05-21 Sieć Badawcza Łukasiewicz – Port Polski Osrodek Rozwoju Technologii Functionalized circular rna and methods and intermediates for their production
WO2026112050A2 (en) 2024-11-21 2026-05-28 Modernatx, Inc. Claudin 6 binding molecules, nucleic acids encoding same, and methods of use
WO2026122882A2 (en) 2024-12-06 2026-06-11 Modernatx, Inc. Solid tumor t cell engagers and uses thereof
WO2026126175A2 (en) 2024-12-15 2026-06-18 Pfizer Inc. Immunogenic compositions against influenza
US20260166136A1 (en) 2024-12-18 2026-06-18 Pfizer Inc. Immunogenic compositions and uses thereof
WO2026151698A1 (en) 2025-01-07 2026-07-16 Modernatx, Inc. Lag3 binding molecules, nucleic acids encoding same, and methods of use
WO2026155976A1 (en) 2025-01-14 2026-07-23 Modernatx, Inc. Pd-1 binding proteins, nucleic acids encoding same, and methods of use
WO2026165118A1 (en) 2025-01-29 2026-08-06 Strand Therapeutics Inc. Polynucleotides comprising detargeting sensors and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ277616A (en) * 1993-11-16 1997-12-19 Genta Inc Synthetic oligomers having phosphonate internucleosidyl linkages of undefined chirality mixed with non-phosphate internucleosidyl linkages
US6060456A (en) * 1993-11-16 2000-05-09 Genta Incorporated Chimeric oligonucleoside compounds
US7074596B2 (en) * 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
US7368439B2 (en) * 2005-06-15 2008-05-06 Bar - Ilan University Dinucleoside poly(borano)phosphate derivatives and uses thereof

Also Published As

Publication number Publication date
US8519110B2 (en) 2013-08-27
JP5715560B2 (ja) 2015-05-07
CA2727091C (en) 2017-05-09
CA2727091A1 (en) 2009-12-10
AU2009256131A1 (en) 2009-12-10
WO2009149253A2 (en) 2009-12-10
EP2297175A2 (en) 2011-03-23
PL2297175T3 (pl) 2014-01-31
WO2009149253A3 (en) 2010-03-25
PL215513B1 (pl) 2013-12-31
EP2297175A4 (en) 2011-06-15
ES2425781T3 (es) 2013-10-17
US20110092574A1 (en) 2011-04-21
AU2009256131B2 (en) 2013-05-30
EP2297175B1 (en) 2013-08-07
JP2011522542A (ja) 2011-08-04

Similar Documents

Publication Publication Date Title
ZA200904684B (en) Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them
PL2350043T3 (pl) Ulepszone aminolipidy i sposoby dostarczania kwasów nukleinowych
SMT202000411T1 (it) Proteine f di rsv modificare e metodi per il loro uso
EP3460064B8 (en) Efficient protein expression in vivo using modified rna (mod-rna)
IL248723B (en) Specific antibodies against the bcr complex and methods of using them
EP2288365A4 (en) TARGETED COOLING FACTORS AND METHOD OF APPLICATION THEREFOR
ZA201106620B (en) Axmi-001,axmi-002,axmi-030,axmi-035,and axmi-045:insecticidal proteins from bacillus thuringiensis and methods for their use
MX2012007684A (es) Modificacion covalente ligando dirigida de proteina.
ZA200900044B (en) Connector for detonator, corresponding booster assembly, and method of use
WO2012045082A3 (en) Engineered nucleic acids and methods of use thereof
SI1935331T1 (sl) Postopek za pripravo modificiranih elektrod, elektrode pripravljene z omenjenim postopkom in encimatski biosenzorji, ki obsegajo omenjene elektrode
PT2057274E (pt) Fosfolípases, ácidos nucleicos que as codificam e métodos de preparação e utilização das mesmas
IL193604A0 (en) Methods of using antibodies against human il-22
WO2011160052A3 (en) Methods and compositions for sequence specific rna endonucleases
GB0705140D0 (en) Charged particle analyser system and method
IL212123A0 (en) Method of making biologically active alpha-beta peptides
GB0811856D0 (en) Magnetic microbubbles, methods of preparing them and their uses
IL208732A0 (en) Methods for enhanced production of bone morphogenetic proteins
EP2238261A4 (en) ISOMERASES, NUCLEIC ACIDS ENCODING THEM AND METHODS OF MAKING THE USE THEREOF
IL207799A0 (en) Azetidine-derived compounds, preparation method therefor and therapeutic use of same
WO2013055418A3 (en) Cross-protective arenavirus vaccines and their method of use
AU2009231892A8 (en) Methods of diagnosing, preventing and treating bone mass diseases
IL221447A0 (en) Method for activation and conjugation of biomolecules
IL197811A0 (en) Means and methods of enhancing delivery to biological systems
TW200833751A (en) Method for preparing polyester nanocomposites